|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J; International Adjuvant
Lung Cancer Trial Collaborative Group, : Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oliver TG, Mercer KL, Sayles LC, Burke JR,
Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, et
al: Chronic cisplatin treatment promotes enhanced damage repair and
tumor progression in a mouse model of lung cancer. Genes Dev.
24:837–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stewart DJ: Mechanisms of resistance to
cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maroun JA, Anthony LB, Blais N, Burkes R,
Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent
MD and Wong R: Prevention and management of chemotherapy-induced
diarrhea in patients with colorectal cancer: A consensus statement
by the Canadian working group on chemotherapy-induced diarrhea.
Curr Oncol. 14:13–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo F, Gu J, Chen L and Xu X: Systems
pharmacology strategies for anticancer drug discovery based on
natural products. Mol Biosyst. 10:1912–1917. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asano J, Chiba K, Tada M and Yoshii T:
Cytotoxic xanthones from Garcinia hanburyi. Phytochemistry.
41:815–820. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan F, Wang M, Chen H, Su J, Wang X, Wang
F, Xia L and Li Q: Gambogenic acid mediated apoptosis through the
mitochondrial oxidative stress and inactivation of Akt signaling
pathway in human nasopharyngeal carcinoma CNE-1 cells. Eur J
Pharmacol. 652:23–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen HB, Zhou LZ, Mei L, Shi XJ, Wang XS,
Li QL and Huang L: Gambogenic acid-induced time- and dose-dependent
growth inhibition and apoptosis involving Akt pathway inactivation
in U251 glioblastoma cells. J Nat Med. 66:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu XJ, Han QB, Wen ZS, Ma L, Gao J and
Zhou GB: Gambogenic acid induces G1 arrest via GSK3β-dependent
cyclin D1 degradation and triggers autophagy in lung cancer cells.
Cancer Lett. 322:185–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan F, Wang M, Li J, Cheng H, Su J, Wang
X, Wu H, Xia L, Li X, Chang HC and Li Q: Gambogenic acid induced
mitochondrial-dependent apoptosis and referred to phospho-Erk1/2
and phospho-p38 MAPK in human hepatoma HepG2 cells. Environ Toxicol
Pharmacol. 33:181–190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu P, Wu X, Dai L, Ge Z, Gao C, Zhang H,
Wang F, Zhang X and Chen B: Gambogenic acid exerts antitumor
activity in hypoxic multiple myeloma cells by regulation of miR-21.
J Cancer. 8:3278–3286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen F, Zhang XH, Hu XD, Zhang W, Lou ZC,
Xie LH, Liu PD and Zhang HQ: Enhancement of radiotherapy by ceria
nanoparticles modified with neogambogic acid in breast cancer
cells. Int J Nanomedicine. 10:4957–4969. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su J, Cheng H, Zhang D, Wang M, Xie C, Hu
Y, Chang HC and Li Q: Synergistic effects of 5-fluorouracil and
gambogenic acid on A549 cells: Activation of cell death caused by
apoptotic and necroptotic mechanisms via the ROS-mitochondria
pathway. Biol Pharm Bull. 37:1259–1268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He Y, Ding J, Lin Y, Li J, Shi Y, Wang J,
Zhu Y, Wang K and Hu X: Gambogenic acid alters chemosensitivity of
breast cancer cells to Adriamycin. BMC Complement Altern Med.
15:1812015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Cao W, Zhang J, Yan M, Xu Q, Wu X,
Wan L, Zhang Z, Zhang C, Qin X, et al: A covalently bound inhibitor
triggers EZH2 degradation through CHIP-mediated ubiquitination.
EMBO J. 36:1243–1260. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pertea M, Pertea GM, Antonescu CM, Chang
TC, Mendell JT and Salzberg SL: StringTie enables improved
reconstruction of a transcriptome from RNA-seq reads. Nat
Biotechnol. 33:290–295. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frazee AC, Pertea G, Jaffe AE, Langmead B,
Salzberg SL and Leek JT: Ballgown bridges the gap between
transcriptome assembly and expression analysis. Nat Biotechnol.
33:243–246. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
The Gene Ontology Consortium: The gene
ontology resource: 20 years and still GOing strong. Nucleic Acids
Res. 47(D1): D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kanehisa M, Sato Y, Furumichi M, Morishima
K and Tanabe M: New approach for understanding genome variations in
KEGG. Nucleic Acids Res. 47(D1): D590–D595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanehisa M: Toward understanding the
origin and evolution of cellular organisms. Protein Sci.
28:1947–1951. 2019. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang T, Zhang H, Wang X, Xu L, Jia J and
Zhu X: Gambogenic acid inhibits the proliferation of small-cell
lung cancer cells by arresting the cell cycle and inducing
apoptosis. Oncol Rep. 41:1700–1706. 2019.PubMed/NCBI
|
|
31
|
Huang X, Chen YJ, Peng DY, Li QL, Wang XS,
Wang DL and Chen WD: Solid lipid nanoparticles as delivery systems
for gambogenic acid. Colloids Surf B Biointerfaces. 102:391–397.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin T, Huang X, Wang Y, Zhu T, Luo Q, Wang
X, Zhou K, Cheng H, Peng D and Chen W: Long circulation
nanostructured lipid carriers for gambogenic acid: Formulation
design, characterization, and pharmacokinetic. Xenobiotica.
47:793–799. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo Q, Lin T, Zhang CY, Zhu T, Wang L, Ji
Z, Jia B, Ge T, Peng D and Chen W: A novel glyceryl
monoolein-bearing cubosomes for gambogenic acid: Preparation,
cytotoxicity and intracellular uptake. Int J Pharm. 493:30–39.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin TY, Zhu TT, Xun Y, Tao YS, Yang YQ,
Xie JL, Zhang XM, Chen SX, Ding BJ and Chen WD: A novel drug
delivery system of mixed micelles based on poly(ethylene
glycol)-poly(lactide) and poly(ethylene
glycol)-poly(varepsilon-caprolactone) for gambogenic acid.
Kaohsiung J Med Sci. 35:757–764. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Goyeneche AA, Caron RW and Telleria CM:
Mifepristone inhibits ovarian cancer cell growth in vitro and in
vivo. Clin Cancer Res. 13:3370–3379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu H, Wang Z, Jin S, Hao H, Zheng L, Zhou
B, Zhang W, Lv H and Yuan Y: Dux4 induces cell cycle arrest at G1
phase through upregulation of p21 expression. Biochem Biophys Res
Commun. 446:235–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Giacinti C and Giordano A: RB and cell
cycle progression. Oncogene. 25:5220–5227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rader J, Russell MR, Hart LS, Nakazawa MS,
Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin
SJ, et al: Dual CDK4/CDK6 inhibition induces cell-cycle arrest and
senescence in neuroblastoma. Clin Cancer Res. 19:6173–6182. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu S, Cetinkaya C, Munoz-Alonso MJ, von
der Lehr N, Bahram F, Beuger V, Eilers M, Leon J and Larsson LG:
Myc represses differentiation-induced p21CIP1 expression via
Miz-1-dependent interaction with the p21 core promoter. Oncogene.
22:351–360. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee EW, Lee MS, Camus S, Ghim J, Yang MR,
Oh W, Ha NC, Lane DP and Song J: Differential regulation of p53 and
p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis.
EMBO J. 28:2100–2113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tibbetts RS, Brumbaugh KM, Williams JM,
Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C and Abraham RT: A
role for ATR in the DNA damage-induced phosphorylation of p53.
Genes Dev. 13:152–157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu G and Lozano G: p21 stability: Linking
chaperones to a cell cycle checkpoint. Cancer Cell. 7:113–114.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li J and Yuan J: Caspases in apoptosis and
beyond. Oncogene. 27:6194–6206. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Thornberry NA and Lazebnik Y: Caspases:
Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Saraste A and Pulkki K: Morphologic and
biochemical hallmarks of apoptosis. Cardiovasc Res. 45:528–537.
2000. View Article : Google Scholar : PubMed/NCBI
|
